Tumor Angiogenic Marker Expression Levels during Tumor Growth: Longitudinal Assessment with Molecularly Targeted Microbubbles and US Imaging
- 1 March 2011
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 258 (3), 804-811
- https://doi.org/10.1148/radiol.10101079
Abstract
Purpose To evaluate the use of molecularly targeted microbubbles (MBs) and ultrasonography (US) in the noninvasive assessment of the level of expression of three angiogenic markers, αvβ3 integrin, endoglin, and vascular endothelial growth factor receptor (VEGFR) 2, on tumor vascular endothelial cells in vivo during tumor growth. Materials and Methods All procedures using laboratory animals were approved by the Institutional Administrative Panel on Laboratory Animal Care. Binding specificity of three types of targeted MBs (MBIntegrin, MBEndoglin, MBVEGFR2) was tested in cell culture under flow shear stress conditions. In vivo targeted contrast material–enhanced US imaging signal using the three MB types was measured at three tumor stages (small, medium, large) in three subcutaneous cancer xenografts (breast, ovarian, pancreatic cancer) in mice (n = 54). In vivo US imaging signal was correlated with ex vivo angiogenic marker expression. Significant differences were evaluated by using the Student t, analysis of variance, Wilcoxon, and Tukey Honest Significant Difference tests. Results Cell attachment of all three MB types was significantly (P = .016) higher compared with control MBs, and this attachment could be significantly (P = .026) decreased by blocking antibodies. Angiogenic marker–expressing cells bound significantly (P = .003) more targeted MBs than negative control cells, and MB attachment significantly (P < .001) correlated with marker expression levels on cells (ρ = 0.87). In early stage breast and ovarian cancers, in vivo targeted contrast-enhanced US demonstrated significantly (P ≤ .04) higher endoglin expression than both αvβ3 integrin and VEGFR2 expression, whereas in early stage pancreatic cancer, marker expressions were not significantly different (P ≥ .07). There was good correlation (ρ ≥ 0.63; P ≤ .05) between in vivo targeted contrast-enhanced US imaging signals using the three MB types and ex vivo immunoblotting results regarding expression levels of the three angiogenic markers. Immunofluorescence confirmed expression of αvβ3 integrin, endoglin, and VEGFR2 on tumor vascular endothelial cells. Conclusion Targeted contrast-enhanced US imaging allows noninvasive in vivo assessment of the expression levels of αvβ3 integrin, endoglin, and VEGFR2, which vary during tumor growth in subcutaneous cancer xenografts. © RSNA, 2011 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10101079/-/DC1Keywords
This publication has 26 references indexed in Scilit:
- Antiangiogenic Cancer Therapy: Monitoring with Molecular US and a Clinically Translatable Contrast Agent (BR55)Radiology, 2010
- Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast Microbubbles Conjugated to Integrin-Binding Knottin PeptidesJournal of Nuclear Medicine, 2010
- The emerging role of TGF-β superfamily coreceptors in cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Angiogenesis and ovarian cancerClinical and Translational Oncology, 2009
- [Expression of selected angiogenesis markers and modulators in pre-, peri- and postmenopausal women with ovarian cancer].2009
- Anti-angiogenesis therapy in pancreatic carcinoma.2006
- Tumorigenesis and the angiogenic switchNature Reviews Cancer, 2003
- Endoglin (CD105): a target for anti-angiogenetic cancer therapy.Current Drug Targets, 2003
- Role of integrins in cell invasion and migrationNature Reviews Cancer, 2002
- Function and interactions of integrinsCell and tissue research, 2001